Previous close | 9.65 |
Open | 9.70 |
Bid | 9.67 x 400 |
Ask | 9.80 x 300 |
Day's range | 9.46 - 9.76 |
52-week range | 8.82 - 21.00 |
Volume | |
Avg. volume | 639,069 |
Market cap | 1.551B |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.59 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 25.25 |
Insiders were net buyers of Neumora Therapeutics, Inc.'s ( NASDAQ:NMRA ) stock during the past year. That is, insiders...
Potential to alleviate unmet need associated with depressed mood and anhedonia in bipolar depression; navacaprant has demonstrated the ability to improve these symptoms in MDD in a Phase 2 study Navacaprant is also currently in Phase 3 development for the treatment of MDD with data from KOASTAL-1 anticipated in the fourth quarter of 2024 WATERTOWN, Mass., May 14, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company with a therapeutics pip
On-track to report topline Phase 3 data from KOASTAL-1 study with navacaprant in MDD; guidance narrowed to fourth quarter of 2024 Multiple clinical study initiations planned in second quarter of 2024, including Phase 2 study in bipolar depression with navacaprant and Phase 1b study in Alzheimer's disease agitation with NMRA-511 Strong financial position with $423.0 million in cash, cash equivalents and marketable securities expected to support operations into 2026, providing runway through multi